In December 2025, Palvella requested a Preliminary Breakthrough Therapy Designation Advice meeting with the FDA which is anticipated for the first quarter of 2026. The Company plans to commence a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback